Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
1,225 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05703555 | INTRUSION: Unraveling the INTRatUmoral PK/PD relatION for SAR408701(INTRUSION) | withdrawn | Phase 2 | 0 | Erasmus Medical CenterOTHER | 1 | Feb 28, 2024 | clinicaltrials |
| NCT03709706 | Pilot Immunotherapy Study With Letetresgene Autoleucel (Lete-cel, GSK3377794)T-cells in New York Esophageal Squamous Cell Carcinoma-1 (NY-ESO-1)/ LAGE-1a-positive Advanced Non-small Cell Lung Cancer (NSCLC) Either Alone or in Combination With Pembrolizumab | terminated | Phase 1 / Phase 2 | 34 | GlaxoSmithKlineINDUSTRY |
| 5 |
| Feb 23, 2024 |
| clinicaltrials |
| NCT03620578 | DA-EPOCH-R Induction Followed by Nivolumab Consolidation in Newly Diagnosed MYC, BCL2 and/or BCL6 Rearranged HGBL(HO152) | active not recruiting | Phase 2 | 97 | Stichting Hemato-Oncologie voor Volwassenen NederlandOTHER | 2 | Feb 14, 2024 | clinicaltrials |
| NCT03834220 | Basket Trial in Solid Tumors Harboring a Fusion of FGFR1, FGFR2 or FGFR3- (FUZE Clinical Trial) | terminated | Phase 2 | 63 | Debiopharm International SAINDUSTRY | 23 | Feb 7, 2024 | clinicaltrials |
| NCT03838042 | INFORM2 Study Uses Nivolumab and Entinostat in Children and Adolescents With High-risk Refractory Malignancies | recruiting | Phase 1 / Phase 2 | 91 | University Hospital HeidelbergOTHER | 7 | Feb 7, 2024 | clinicaltrials |
| NCT04310410 | Feasibility of Combined Focused Ultrasound and Radiotherapy Treatment in Patients With Painful Bone Metastasis(PRE-FURTHER) | completed | Phase 1 / Phase 2 | 10 | UMC UtrechtOTHER | 1 | Feb 7, 2024 | clinicaltrials |
| NCT05430555 | A Phase 1/ 2, First-in-Human, Open-Label, Accelerated-Titration, Two-Part Clinical Trial of TK-8001 in Patients With HLA-A*02:01 Genotype and Advanced-Stage/ Metastatic MAGE-A1+ Solid Tumors(IMAG1NE) | terminated | Phase 1 / Phase 2 | 23 | T-knife GmbHINDUSTRY | 5 | Feb 7, 2024 | clinicaltrials |
| NCT03610360 | DENdritic Cell Immunotherapy for Mesothelioma(DENIM) | completed | Phase 2 / Phase 3 | 176 | Amphera BVINDUSTRY | 5 | Feb 1, 2024 | clinicaltrials |
| NCT03691207 | A Study Of AL101In Patients With Adenoid Cystic Carcinoma (ACC) Bearing Activating Notch Mutations(ACCURACY) | completed | Phase 2 | 87 | Ayala Pharmaceuticals, Inc,INDUSTRY | 6 | Jan 31, 2024 | clinicaltrials |
| NCT02152956 | Flotetuzumab in Primary Induction Failure (PIF) or Early Relapse (ER) Acute Myeloid Leukemia (AML)(VOYAGE) | terminated | Phase 1 / Phase 2 | 244 | MacroGenicsINDUSTRY | 8 | Jan 30, 2024 | clinicaltrials |
| NCT01320085 | A Phase II Study of Single Agent MEK162 in Patients With Advanced Melanoma | completed | Phase 2 | 183 | PfizerINDUSTRY | 5 | Jan 24, 2024 | clinicaltrials |
| NCT02925234 | The Drug Rediscovery Protocol (DRUP Trial)(DRUP) | recruiting | Phase 2 | 1,550 | The Netherlands Cancer InstituteOTHER | 1 | Jan 24, 2024 | clinicaltrials |
| NCT03840902 | M7824 With cCRT in Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) | terminated | Phase 2 | 153 | EMD Serono Research & Development Institute, Inc.INDUSTRY | 15 | Jan 16, 2024 | clinicaltrials |
| NCT04212377 | Dendritic Cells for Immunotherapy of Metastatic Endometrial Cancer Patients(DECENDO) | completed | Phase 2 | 8 | Radboud University Medical CenterOTHER | 1 | Jan 11, 2024 | clinicaltrials |
| NCT03149549 | PROCLAIM-CX-2009: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2009 for Patients With Selected Solid Tumors | terminated | Phase 1 / Phase 2 | 99 | CytomX TherapeuticsINDUSTRY | 4 | Jan 5, 2024 | clinicaltrials |
| NCT03669718 | A Randomized Phase 2 Study of Cemiplimab ± ISA101b in HPV16-Positive OPC | unknown | Phase 2 | 194 | ISA PharmaceuticalsINDUSTRY | 13 | Dec 29, 2023 | clinicaltrials |
| NCT04151563 | A Clinical Study Evaluating Nivolumab-containing Treatments in Patients With Advanced Non-small Cell Lung Cancer After Failing Previous PD-1/(L)1 Therapy and Chemotherapy(CheckMate 79X) | withdrawn | Phase 1 / Phase 2 | 0 | Bristol-Myers SquibbINDUSTRY | 10 | Dec 19, 2023 | clinicaltrials |
| NCT02969083 | Feasibility of Neo-adjuvant Versus Adjuvant Chemotherapy in Upper Tract Urothelial Carcinoma(URANUS) | unknown | Phase 2 | 200 | The European Uro-Oncology GroupOTHER | 3 | Dec 18, 2023 | clinicaltrials |
| NCT02684058 | Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Pediatric Patients With BRAF V600 Mutation Positive LGG or Relapsed or Refractory HGG Tumors | completed | Phase 2 | 151 | Novartis PharmaceuticalsINDUSTRY | 20 | Dec 13, 2023 | clinicaltrials |
| NCT03638375 | TIL and Anti-PD1 in Metastatic Melanoma(ACTME) | unknown | Phase 1 / Phase 2 | 34 | Leiden UniversityOTHER | 1 | Dec 12, 2023 | clinicaltrials |
| NCT01402271 | Pazopanib Hydrochloride, Paclitaxel, and Carboplatin in Treating Patients With Refractory or Resistant Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer | completed | Phase 1 / Phase 2 | 88 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 3 | Dec 11, 2023 | clinicaltrials |
| NCT01524926 | CREATE: Cross-tumoral Phase 2 With Crizotinib(CREATE) | completed | Phase 2 | 582 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 10 | Dec 11, 2023 | clinicaltrials |
| NCT02608268 | Phase I-Ib/II Study of MBG453 as Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies | terminated | Phase 1 / Phase 2 | 252 | Novartis PharmaceuticalsINDUSTRY | 9 | Dec 6, 2023 | clinicaltrials |
| NCT04729543 | MAGE-C2 TCR T Cell Trial to Treat Melanoma and Head and Neck Cancer(MC2TCR) | recruiting | Phase 1 / Phase 2 | 20 | Erasmus Medical CenterOTHER | 1 | Dec 4, 2023 | clinicaltrials |
| NCT04045717 | Hypofractionated Focal Lesion Ablative Microboost in prostatE Cancer 2.0 | active not recruiting | Phase 2 | 124 | Universitaire Ziekenhuizen KU LeuvenOTHER | 2 | Dec 1, 2023 | clinicaltrials |
| NCT00819156 | Dose Finding Trial With a New Treatment (Degarelix) for Prostate Cancer | completed | Phase 2 | 189 | Ferring PharmaceuticalsINDUSTRY | 8 | Nov 30, 2023 | clinicaltrials |
| NCT02181738 | Study of Nivolumab in Patients With Classical Hodgkin's Lymphoma (Registrational)(CheckMate 205) | completed | Phase 2 | 294 | Bristol-Myers SquibbINDUSTRY | 10 | Nov 28, 2023 | clinicaltrials |
| NCT04518124 | Propranolol in Angiosarcoma | completed | Phase 2 | 14 | The Netherlands Cancer InstituteOTHER | 1 | Nov 22, 2023 | clinicaltrials |
| NCT02733042 | A Study to Determine Dose, Safety, and Efficacy of Durvalumab as Monotherapy and in Combination Therapy in Subjects With Lymphoma or Chronic Lymphocytic Leukemia(FUSION NHL 001) | completed | Phase 1 / Phase 2 | 106 | CelgeneINDUSTRY | 7 | Nov 18, 2023 | clinicaltrials |
| NCT02527434 | Study of Tremelimumab in Patients With Advanced Solid Tumors | completed | Phase 2 | 64 | AstraZenecaINDUSTRY | 5 | Nov 15, 2023 | clinicaltrials |
| NCT02977052 | Optimal Neo-adjuvant Combination Scheme of Ipilimumab and Nivolumab(OpACIN-neo) | unknown | Phase 2 | 186 | The Netherlands Cancer InstituteOTHER | 4 | Nov 15, 2023 | clinicaltrials |
| NCT01972217 | Ph II Study to Evaluate Olaparib With Abiraterone in Treating Metastatic Castration Resistant Prostate Cancer. | completed | Phase 2 | 158 | AstraZenecaINDUSTRY | 11 | Nov 14, 2023 | clinicaltrials |
| NCT02488759 | An Investigational Immuno-therapy Study to Investigate the Safety and Effectiveness of Nivolumab, and Nivolumab Combination Therapy in Virus-associated Tumors(CheckMate358) | completed | Phase 1 / Phase 2 | 578 | Bristol-Myers SquibbINDUSTRY | 11 | Nov 13, 2023 | clinicaltrials |
| NCT03673826 | Carfilzomib, Lenalidomide and Dexamethasone Versus Lenalidomide and Dexamethasone in High- Risk SMM(HO147SMM) | active not recruiting | Phase 2 | 58 | Stichting Hemato-Oncologie voor Volwassenen NederlandOTHER | 4 | Nov 1, 2023 | clinicaltrials |
| NCT01750281 | Assess Efficacy and Safety of AZD6244 in Combination With Docetaxel in Patients Receiving Second Line Non Small Cell Lung Cancer Treatment.(SELECT-2) | completed | Phase 2 | 212 | AstraZenecaINDUSTRY | 8 | Oct 24, 2023 | clinicaltrials |
| NCT03003637 | ImmunoModulation by the Combination of Ipilimumab and Nivolumab Neoadjuvant to Surgery In Advanced or Recurrent Head and Neck Carcinoma(IMCISION) | completed | Phase 1 / Phase 2 | 33 | The Netherlands Cancer InstituteOTHER | 1 | Oct 23, 2023 | clinicaltrials |
| NCT04648189 | Cetuxibab to Reduce Circulating Tumor Cells in Early Stage NSCLC | withdrawn | Phase 2 | 0 | The Netherlands Cancer InstituteOTHER | 1 | Oct 19, 2023 | clinicaltrials |
| NCT03727724 | Afatinib and Cetuximab in Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Positive Non-small-cell Lung Cancer(AFACET) | completed | Phase 2 | 37 | The Netherlands Cancer InstituteOTHER | 1 | Oct 18, 2023 | clinicaltrials |
| NCT06079333 | NEO- and Adjuvant Targeted Therapy in Braf-mutated Anaplastic Cancer of the Thyroid (NEO-ATACT Study)(NEO-ATACT) | recruiting | Phase 2 | 20 | Leiden University Medical CenterOTHER | 1 | Oct 12, 2023 | clinicaltrials |
| NCT02685826 | A Study of Durvalumab in Combination With Lenalidomide With and Without Dexamethasone in Adults With Newly Diagnosed Multiple Myeloma | completed | Phase 1 / Phase 2 | 56 | CelgeneINDUSTRY | 8 | Oct 6, 2023 | clinicaltrials |
| NCT04167618 | 177Lu-DTPA-Omburtamab Radioimmunotherapy for Recurrent or Refractory Medulloblastoma | terminated | Phase 1 / Phase 2 | 2 | Y-mAbs TherapeuticsINDUSTRY | 5 | Oct 6, 2023 | clinicaltrials |
| NCT05555017 | Tracer-Guided Surgery for Recurrent Prostate Cancer(Trace-II) | unknown | Phase 2 | 60 | The Netherlands Cancer InstituteOTHER | 1 | Oct 6, 2023 | clinicaltrials |
| NCT01446744 | Stereotactic Ablative Radiotherapy for Comprehensive Treatment of Oligometastatic Tumors (SABR-COMET)(SABR-COMET) | unknown | Phase 2 | 99 | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sOTHER | 4 | Oct 5, 2023 | clinicaltrials |
| NCT02272790 | Adavosertib Plus Chemotherapy in Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | completed | Phase 2 | 95 | AstraZenecaINDUSTRY | 3 | Oct 3, 2023 | clinicaltrials |
| NCT05906615 | Intravenous Lidocaine for Pain Associated With Pancreatic Cancer and Chronic Pancreatitis(LIDOPAN) | completed | Phase 2 | 30 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)OTHER | 1 | Oct 2, 2023 | clinicaltrials |
| NCT06028048 | Enhancing Work Participation of Unemployed and Work-Disabled Cancer Survivors(PLACES) | unknown | Phase 2 / Phase 3 | 164 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)OTHER | 1 | Sep 29, 2023 | clinicaltrials |
| NCT03565991 | Javelin BRCA/ATM: Avelumab Plus Talazoparib in Patients With BRCA or ATM Mutant Solid Tumors | terminated | Phase 2 | 202 | PfizerINDUSTRY | 9 | Sep 25, 2023 | clinicaltrials |
| NCT03379909 | Phase II Study of Oral Metformin for Intravesical Treatment of Non-muscle-invasive Bladder Cancer(TROJAN) | recruiting | Phase 2 | 49 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)OTHER | 1 | Sep 21, 2023 | clinicaltrials |
| NCT03686332 | PEnile Cancer Radio- and Immunotherapy CLinical Exploration Study(PERICLES) | completed | Phase 2 | 32 | The Netherlands Cancer InstituteOTHER | 1 | Sep 21, 2023 | clinicaltrials |
| NCT01485861 | Study of Ipatasertib or Apitolisib With Abiraterone Acetate Versus Abiraterone Acetate in Participants With Castration-Resistant Prostate Cancer Previously Treated With Docetaxel Chemotherapy | completed | Phase 1 / Phase 2 | 298 | Genentech, Inc.INDUSTRY | 9 | Sep 14, 2023 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials